HB-EGF (Heparin-Binding EGF-Like Growth Factor)
Living reference work entry
Since the discovery of epidermal growth factor (EGF) in 1962, a total of seven mammalian ligands that bind the EGF receptor (EGFR/ErbB1) have been identified, including transforming growth factor-α (TGFα), amphiregulin (ARG), betacellulin (BTC), epiregulin (ERG), epigen (EPG), and heparin-binding EGF-like growth factor (HB-EGF) (Harris et al. 2003). Historically, HB-EGF was the fourth growth factor to be identified among EGFR-ligands. Major findings regarding HB-EGF are:
Discovery of HB-EGF (Higashiyama et al. 1991)
Identification of HB-EGF’s major role in EGFR transactivation (Prenzel et al. 1999)
Proof of the physiological significance of HB-EGF shedding...
KeywordsRapidly Progressive Glomerulonephritis EGFR Activation Epidermal Growth Factor Family EGFR Ligand Diphtheria Toxin Receptor
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- Iwamoto R, Higashiyama S, Mitamura T, Taniguchi N, Klagsbrun M, Mekada E. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J. 1994;13:2322–30.PubMedPubMedCentralGoogle Scholar
- Koshikawa N, Mizushima H, Minegishi T, Iwamoto R, Mekada E, Seiki M. Membrane type 1-matrix metalloproteinase cleaves off the NH2-terminal portion of heparin-binding epidermal growth factor and converts it into a heparin-independent growth factor. Cancer Res. 2010;70:6093–103. doi:10.1158/0008-5472.CAN-10-0346.CrossRefPubMedGoogle Scholar
- Mekada E, Iwamoto R. HB-EGF. UCSD-Nature Molecule Pages. 2008. doi:10.1038/mp.a002932.01.Google Scholar
- Murata T, Mizushima H, Chinen I, Moribe H, Yagi S, Hoffman RM, et al. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. Cancer Res. 2011;71:6632–42. doi:10.1158/0008-5472.CAN-11-0034.CrossRefGoogle Scholar
- Oyagi A, Morimoto N, Hamanaka J, Ishiguro M, Tsuruma K, Shimazawa M, et al. Forebrain-specific heparin-binding epidermal growth factor-like growth factor knockout mice show exacerbated ischemia and reperfusion injury. Neuroscience. 2011;185:116–24. doi:10.1016/j.neuroscience.2011.04.034.CrossRefPubMedGoogle Scholar
- Svensson KJ, Kucharzewska P, Christianson HC, Skold S, Lofstedt T, Johansson MC, et al. Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc Natl Acad Sci USA. 2011;108:13147–52. doi:10.1073/pnas.1104261108.CrossRefPubMedPubMedCentralGoogle Scholar
- Takemura T, Yoshida Y, Kiso S, Saji Y, Ezaki H, Hamano M, et al. Conditional knockout of heparin-binding epidermal growth factor-like growth factor in the liver accelerates carbon tetrachloride-induced liver injury in mice. Hepatol Res. 2013a;43:384–93. doi:10.1111/j.1872-034X.2012.01074.x.CrossRefPubMedGoogle Scholar
© Springer Science+Business Media LLC 2016